TCDA News and Press, Tricida Inc. From 08/09/21

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic ...

SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2021 financial results after the close of market on Monday, August 9, 2021. Tricida will host a conference call and webcast at 4:30 pm East...

SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 42 nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 12:50 pm PT / 3:50 pm ET. Gerrit Klaerner, Tricida’s ...

Tricida, Inc. (TCDA) Q1 2021 Earnings Conference Call May 6, 2021 16:30 ET Company Participants Jackie Cossmon - Vice President of Investor Relations & Communications Gerrit Klaerner - Founder, President & Chief Executive Officer Geoff Parker - Chief Financial Officer Conference Call ...

TRICIDIA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Tricida, Inc. - TCDA TRICIDIA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Of...

SOUTH SAN FRANCISCO, May 06, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 6th by Tricida, Inc. (Nasdaq: TCDA), please note that the first and second bullets of the "Upcoming Milestones" should have been combined into one bullet. The co...

Tricida (TCDA): Q1 GAAP EPS of -$1.06 misses by $0.03.Cash, cash equivalents and Short-term investments of $217.7MPress Release For further details see: Tricida EPS misses by $0.03

SOUTH SAN FRANCISCO, May 06, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidos...

SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2021 financial results after the close of market on Thursday, May 6, 2021. Tricida will host a conference call and webcast at 4:30 pm Easte...

Today, we take our first in-depth look at Tricida, a small developmental biotech concern. The company has one late-stage asset and Stephen Cohen has acquired a significant stake in the firm through his fund Point72. A full investment analysis on this Busted IPO is presented in the...